Katsuyuki Fukutake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katsuyuki Fukutake has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Morio Arai
Department of Medical Affairs, Shire, Tokyo, Japan
4 shared publicationsAkira Yoshioka
Department of Pediatrics, Nara Medical University, Kashihara, Japan
3 shared publications- Akira Shirahata
Department of Pediatrics, University of Occupational and Environmental Health, Japan
2 shared publications Hideji Hanabusa
2 shared publicationsJunki Takamatsu
The Japanese Red Cross Tokai Hokuriku Block Blood Center, Seto, Japan
2 shared publicationsKimihito Koshihara
2 shared publications
Latest Publications
- 2 January 2019
- Published by Springer Nature in International Journal of Hematology
- Vol. 109 (3) , 336-345
Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan
Rurioctocog alfa (recombinant factor VIII: Advate®) is available for the control of bleeding in patients with hemophilia A in Japan. To evaluate the inhibitor development, safety, and efficacy of rurioctocog alfa, a non-interventional and observational postmarketing surveillance was conducted on 352 previously treated Japanese patients aged 1–76 years with ≥ 4 exposure days under the conditions of routine clinical practice. A post-hoc comparison of the mean annualized bleeding rates which required treatment with rurioctocog alfa detected a statistically significant difference (P < 0.0001) between patients treated on regular prophylaxis (8.5 bleeds/year) and patients treated on an on-demand basis (36.6 bleeds/year). Favorable prophylactic and on-demand hemostatic efficacy (“excellent” or “good”) were shown in 88.5–100% of patients across all treatment regimens. A total of 22 events of adverse drug reactions were reported in 13 male patients. Of the 352 patients, 3 (0.9%) patients, all of whom had ≤ 50 exposure days before enrollment, developed de novo FVIII inhibitor. No deaths or allergic reactions were reported. Rurioctocog alfa was found to be well-tolerated and effective among patients with hemophilia A in a postmarketing routine clinical practice.
- 2 January 2019
- Published by Springer Nature in International Journal of Hematology
- Vol. 109 (3) , 336-345
Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan
Rurioctocog alfa (recombinant factor VIII: Advate®) is available for the control of bleeding in patients with hemophilia A in Japan. To evaluate the inhibitor development, safety, and efficacy of rurioctocog alfa, a non-interventional and observational postmarketing surveillance was conducted on 352 previously treated Japanese patients aged 1–76 years with ≥ 4 exposure days under the conditions of routine clinical practice. A post-hoc comparison of the mean annualized bleeding rates which required treatment with rurioctocog alfa detected a statistically significant difference (P < 0.0001) between patients treated on regular prophylaxis (8.5 bleeds/year) and patients treated on an on-demand basis (36.6 bleeds/year). Favorable prophylactic and on-demand hemostatic efficacy (“excellent” or “good”) were shown in 88.5–100% of patients across all treatment regimens. A total of 22 events of adverse drug reactions were reported in 13 male patients. Of the 352 patients, 3 (0.9%) patients, all of whom had ≤ 50 exposure days before enrollment, developed de novo FVIII inhibitor. No deaths or allergic reactions were reported. Rurioctocog alfa was found to be well-tolerated and effective among patients with hemophilia A in a postmarketing routine clinical practice.
- 1 January 2011
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 22 (5) , 259-265
Support for patients with hemophilia affected by the Great East Japan Earthquake
総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。
- 1 January 2011
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 22 (5) , 259-265
Support for patients with hemophilia affected by the Great East Japan Earthquake
総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。
- Open Access
- 1 January 2001
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 62 (11) , 2627-2630
A Case of Congenital XI Factor Deficiency with Sigmoid Colon Cancer in which Preoperative Plasma Pheresis Successfully Controlled Perioperative Abnormal Bleeding.
術前検査にて先天性第XI因子欠損症と診断され,血漿交換により第XI因子補充を施行し周術期止血コントロールに成功した症例を経験した.症例は58歳男性,既往歴に止血異常はない.健診にて便潜血反応陽性を指摘され,精査にてS状結腸癌の診断を受け手術目的に入院した.術前凝固能検査にてAPTTの延長を認め,精査にて第XI因子活性が1.8%と低値を示し先天性第XI因子欠損症と診断された.術前血漿交換により第XI因子活性を35%にすることでS状結腸切除術の周術期に異常出血を回避できた.また本症例は術前禁食期間に直接ビリルビンの上昇を認め, Gilbert症候群を合併していた.先天性第XI因子欠損症は本邦では稀な疾患ではあるが,開腹手術に際しては術前血漿交換による第XI因子の補充が有用と考えられた.
- 1 January 2001
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 62 (11) , 2627-2630
Open AccessA Case of Congenital XI Factor Deficiency with Sigmoid Colon Cancer in which Preoperative Plasma Pheresis Successfully Controlled Perioperative Abnormal Bleeding.
術前検査にて先天性第XI因子欠損症と診断され,血漿交換により第XI因子補充を施行し周術期止血コントロールに成功した症例を経験した.症例は58歳男性,既往歴に止血異常はない.健診にて便潜血反応陽性を指摘され,精査にてS状結腸癌の診断を受け手術目的に入院した.術前凝固能検査にてAPTTの延長を認め,精査にて第XI因子活性が1.8%と低値を示し先天性第XI因子欠損症と診断された.術前血漿交換により第XI因子活性を35%にすることでS状結腸切除術の周術期に異常出血を回避できた.また本症例は術前禁食期間に直接ビリルビンの上昇を認め, Gilbert症候群を合併していた.先天性第XI因子欠損症は本邦では稀な疾患ではあるが,開腹手術に際しては術前血漿交換による第XI因子の補充が有用と考えられた.
- 31 December 2000
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. ume 26 (Number 01) , 029-032
Current Status of Hemophilia Patients and Recombinant Coagulation Factor Concentrates in Japan
The first recombinant factor VIII concentrate was introduced in 1987 to treat hemophilia A patients, and the product was licensed in the United States in 1992. More than 10 years have passed since the recombinant products have been used for treatment of hemophilia A. The new therapeutic options seem to be safe and effective through the gathered experiences. Recently, recombinant factor VIIa concentrate has become available to treat hemophilia patients with inhibitor and factor VII deficiency patients in Europe and also recombinant factor IX for the treatment of hemophilia B has been licensed in the United States and Europe. The usage of recombinant coagulation factors has expanded the routine therapy for hemophilia in many countries. In Japan, the consumption of recombinant factor VIII is increasing year by year, because many patients have started to think that the recombinant technology seems to be safe. Unfortunately, though, the factor VIIa and factor IX products have not been licensed yet in Japan. This article discusses the current status of patients with hemophilia and recombinant coagulation factor products in Japan.
- 31 December 2000
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. ume 26 (Number 01) , 029-032
Current Status of Hemophilia Patients and Recombinant Coagulation Factor Concentrates in Japan
The first recombinant factor VIII concentrate was introduced in 1987 to treat hemophilia A patients, and the product was licensed in the United States in 1992. More than 10 years have passed since the recombinant products have been used for treatment of hemophilia A. The new therapeutic options seem to be safe and effective through the gathered experiences. Recently, recombinant factor VIIa concentrate has become available to treat hemophilia patients with inhibitor and factor VII deficiency patients in Europe and also recombinant factor IX for the treatment of hemophilia B has been licensed in the United States and Europe. The usage of recombinant coagulation factors has expanded the routine therapy for hemophilia in many countries. In Japan, the consumption of recombinant factor VIII is increasing year by year, because many patients have started to think that the recombinant technology seems to be safe. Unfortunately, though, the factor VIIa and factor IX products have not been licensed yet in Japan. This article discusses the current status of patients with hemophilia and recombinant coagulation factor products in Japan.
- 1 January 1999
- Published by Japan Society of Transfusion Medicine and Cell Therapy in Journal of the Japan Society of Blood Transfusion
- Vol. 45 (4) , 442-448
Management and Analysis of Occupational Needlestick Accidents.
- 1 January 1999
- Published by Japan Society of Transfusion Medicine and Cell Therapy in Journal of the Japan Society of Blood Transfusion
- Vol. 45 (4) , 442-448
Management and Analysis of Occupational Needlestick Accidents.
- 1 January 1995
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 6 (3) , 174-182
Inhibitory Effect of Iodinated Contrast Media on Blood Coagulation System in vitro
- 1 January 1995
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 6 (3) , 174-182
Inhibitory Effect of Iodinated Contrast Media on Blood Coagulation System in vitro
- 1 January 1994
- Published by The Japanese Association for Infectious Diseases in Kansenshogaku Zasshi
- Vol. 68 (9) , 1093-1104
Phase III Clinical Trial of KRN8601 (rhG-CSF) for Neutropenia in Patients with Human Immunodeficiency Virus Infection
The efficacy of KRN8601 for neutropenia associated with HIV infection was evaluated in 24 patients. KRN8601 was infused intravenously at a dosage of 200μg/m2 for 14 consecutive days. Neutrophil counts recovered in 19 (90.5%) out of 21 evaluable patients by KRN8601 treatment. The concomitant myelosuppressive agents for the treatment of HIV infection and complications could be continued without dose reduction in 15 (88.2%) out of 17 patients.The clinical improvement was observed in 66.7%(12/18) of patients who were treated with anti-mycrobial agents for opportunistic infections which indicates that KRN8601 shows an additive effect on infections when it was given with anti-mycrobial agents.Adverse events and abnormal laboratory findings were observed in 3 and 7 patients, respectively, and they were reversible and tolerable.This study demonstrated that KRN8601 improved neutropenia with HIV infection, made possible to continue the full dose of myelosuppressive treatments and have additive effect on the treatment of secondary infections.
- 1 January 1994
- Published by The Japanese Association for Infectious Diseases in Kansenshogaku Zasshi
- Vol. 68 (9) , 1093-1104
Phase III Clinical Trial of KRN8601 (rhG-CSF) for Neutropenia in Patients with Human Immunodeficiency Virus Infection
The efficacy of KRN8601 for neutropenia associated with HIV infection was evaluated in 24 patients. KRN8601 was infused intravenously at a dosage of 200μg/m2 for 14 consecutive days. Neutrophil counts recovered in 19 (90.5%) out of 21 evaluable patients by KRN8601 treatment. The concomitant myelosuppressive agents for the treatment of HIV infection and complications could be continued without dose reduction in 15 (88.2%) out of 17 patients.The clinical improvement was observed in 66.7%(12/18) of patients who were treated with anti-mycrobial agents for opportunistic infections which indicates that KRN8601 shows an additive effect on infections when it was given with anti-mycrobial agents.Adverse events and abnormal laboratory findings were observed in 3 and 7 patients, respectively, and they were reversible and tolerable.This study demonstrated that KRN8601 improved neutropenia with HIV infection, made possible to continue the full dose of myelosuppressive treatments and have additive effect on the treatment of secondary infections.